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Abstract
Background: To facilitate the clinical implementation of genomic medicine by next-generation sequencing, it will
be critically important to obtain accurate and consistent variant calls on personal genomes. Multiple software tools
for variant calling are available, but it is unclear how comparable these tools are or what their relative merits in
real-world scenarios might be.
Methods: We sequenced 15 exomes from four families using commercial kits (Illumina HiSeq 2000 platform and
Agilent SureSelect version 2 capture kit), with approximately 120X mean coverage. We analyzed the raw data using
near-default parameters with five different alignment and variant-calling pipelines (SOAP, BWA-GATK, BWA-SNVer,
GNUMAP, and BWA-SAMtools). We additionally sequenced a single whole genome using the sequencing and
analysis pipeline from Complete Genomics (CG), with 95% of the exome region being covered by 20 or more
reads per base. Finally, we validated 919 single-nucleotide variations (SNVs) and 841 insertions and deletions
(indels), including similar fractions of GATK-only, SOAP-only, and shared calls, on the MiSeq platform by amplicon
sequencing with approximately 5000X mean coverage.
Results: SNV concordance between five Illumina pipelines across all 15 exomes was 57.4%, while 0.5 to 5.1% of
variants were called as unique to each pipeline. Indel concordance was only 26.8% between three indel-calling
pipelines, even after left-normalizing and intervalizing genomic coordinates by 20 base pairs. There were 11% of
CG variants falling within targeted regions in exome sequencing that were not called by any of the Illumina-based
exome analysis pipelines. Based on targeted amplicon sequencing on the MiSeq platform, 97.1%, 60.2%, and 99.1%
of the GATK-only, SOAP-only and shared SNVs could be validated, but only 54.0%, 44.6%, and 78.1% of the GATK-
only, SOAP-only and shared indels could be validated. Additionally, our analysis of two families (one with four
individuals and the other with seven), demonstrated additional accuracy gained in variant discovery by having
access to genetic data from a multi-generational family.
Conclusions: Our results suggest that more caution should be exercised in genomic medicine settings when
analyzing individual genomes, including interpreting positive and negative findings with scrutiny, especially for
indels. We advocate for renewed collection and sequencing of multi-generational families to increase the overall
accuracy of whole genomes.
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Recent studies have substantiated the prevalence of rare
mutations in the human genome [1,2]. Whole-genome
sequencing (WGS) can uncover substantially more
genetic variation than traditional single-nucleotide poly-
morphism (SNP) arrays, thus explaining a larger fraction
of human phenotypic diversity [3,4]. This in turn is driv-
ing the sequencing of personal genomes aimed at
obtaining highly accurate information about each per-
son’s genome [5,6].
Given the existence of multiple sequencing platforms
and multiple data-analysis pipelines for next-generation
sequencing, researchers and clinicians may be under the
impression that these methods all work similarly to iden-
tify genetic variants from personal genomes. However,
one group recently reported that when variants detected
in the same sample by the 1000 genomes project (1 KGP)
and the Complete Genomics (CG) platform were com-
pared, 19% of the single-nucleotide variants (SNVs)
derived were unique to one dataset [7]. This is likely due
to differences in technology, data collection, read-align-
ment methods, and variant-calling algorithms. The group
further concluded that ‘current research resources and
informatics methods do not adequately account for the
high level of variation that already exists in the human
population, and significant efforts are needed to create
resources that can accurately assess personal genomes
for health, disease, and prediction of treatment outcomes’
[7]. As an illustration of the widely differing methods
currently being used, one of the above-referenced papers
used Illumina sequencing data processed with the Short
Oligonucleotide Analysis Package (SOAP) pipeline [2]
whereas the other group used Illumina sequencing data
processed with the Genome Analysis Toolkit (GATK)
pipeline [1]. Neither group published a comparison of
the overlap (concordance or discordance) between pipe-
lines. Other researchers have worked on establishing a
rigorous filtering pipeline to optimize SNV calling,
reporting that the cumulative application of 12 individual
filters resulted in a 290-fold reduction in the error rate
[8]. Another group has worked to optimize their own
pipeline utilizing, among other things, GATK and SAM-
tools, although it is not clear if this group compared their
results with anything from SOAP [9]. This same group
published a comparison of data obtained using sequen-
cing from Illumina and CG, which showed an unexpect-
edly high level of discordance between the two platforms
[10], which has been debated in blog postings [11,12].
Despite these previous studies comparing technical plat-
forms, there have not been many published systematic eva-
luations of a number of currently used bioinformatics
pipelines when generating variant calls from the same set
of raw sequence data. Additionally, despite the existence of
many variant-calling software tools [13], their concordance
using near-default settings has not been thoroughly investi-
gated, making it difficult to assess the relative effects on
variant calling of differences in sequencing platforms
versus differences in implementations of bioinformatics
pipelines. Ideally, researchers and clinicians should have lit-
tle to no uncertainty about the correct pipeline parameteri-
zations for each sequencing experiment, and hence little
variability with respect to their pipeline implementations;
however this is rarely, if ever, the case. Indeed, knowledge
about the perfect and most appropriate parameterization is
often not available or easily obtainable when performing
in-depth sequence analysis, and, sometimes the ‘correct’
parameters may never be precisely characterized due to the
complex nature of the experiment. Researchers, clinicians
and policy-makers stand to benefit from a greater under-
standing of the variability introduced by imperfect and
non-standardized implementations of the available bioin-
formatics pipelines.
To address this issue, we carried out a study of 15
exomes and one whole genome from 15 research partici-
pants, analyzing the data with a range of different variant-
calling pipelines using near-default parameters. Our
results have significant implications for analyzing personal
genomes from next-generation sequencing experiments.
Methods
Ethics approval
The collection and genomic analysis of the DNA were
approved by the institutional review board at the Univer-
sity of Utah, and written informed consent was obtained
from all study participants. Research was carried out in
compliance with the Helsinki Declaration.
Sample collection
The samples used in our study all came from families of
human research participants ascertained in clinics at the
University of Utah (see Additional file 1, Figure S1 for
pedigrees). Blood samples were collected and genomic
DNA extracted using alkaline lysis and ethanol precipita-
tion (Gentra Puregene; Qiagen Corp., Valencia, CA USA).
DNA was quality-checked on agarose gels and quantified
using a microvolume spectrophotometer (NanoDrop
2000; Thermo Fisher Scientific Inc., West Palm Beach, FL,
USA).
Whole-genome sequencing and analysis with Complete
Genomics
After quality control to ensure lack of genomic degradation,
we sent DNA samples (10 ug) to Complete Genomics (CG)
(Mountain View, CA, USA) for sequencing. The whole-
genome DNA was sequenced using nanoarray-based short-
read sequencing by ligation technology [14], including an
adaptation of the pairwise end-sequencing strategy [15].
Reads were mapped to the Genome Reference Consortium
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all the sequencing data quality control, alignment, and var-
iant calling were performed by CG as part of their sequen-
cing service, using their version 2.0 pipeline [16].
Exome capture and sequencing with Illumina HiSeq2000
Exome capture for all 15 samples was carried out using a
commercially available in-solution method (SureSelect
Human All Exon v2; Agilent Technologies Inc., Wilming-
ton, DE, USA), following the manufacturer’sg u i d e l i n e s .
This method is designed to target all human exons,
regions totaling approximately 44 Mb, covering 98.2% of
the Consensus Coding Sequence (CCDS) database. For the
capture, a DNA-shearing instrument (focused-ultrasonica-
tor; Covaris Inc., Woburn, MA, USA) was used to ran-
domly fragment the pure and high molecular weight
genomic DNA samples (experiments carried out by BGI-
Shenzhen, Shenzhen, China), resulting in DNA fragments
with a base-pair peak of 150 to 200 bp. Adaptors were
then ligated to both ends of the resulting fragments. The
adaptor-ligated templates were purified by magnetic beads
(Agencourt AMPure SPRI; Beckman Coulter Inc., Brea,
CA, USA), and fragments with an insert size of approxi-
mately 250 bp were excised. Extracted DNA was amplified
by ligation-mediated (LM)-PCR, purified, and hybridized
(SureSelect Library; Agilent Technologies) for enrichment.
Hybridized fragments bound to the strepavidin beads,
whereas the unbound non-hybridized fragments were
washed out after 24 hours of hybridization. Captured LM-
PCR products were analyzed using a microfluidics-based
platform (2100 Bioanalyzer; Agilent Technologies) to esti-
mate the magnitude of the enrichment. Paired-end
sequencing was performed using a sequencing platform
(HiSeq2000; Illumina Inc., San Diego, CA, USA) with aver-
age read lengths of 90 bp. Raw image files were processed
(Pipeline version 1.6; Illumina Inc.) for base-calling, using
the default parameters. FASTQ files were produced from
the pipeline for downstream sequence data analysis. A
gender check was compatible with the known genders of
the collected human participants.
SNP arrays
DNA samples were genotyped on the SNP arrays
(Human610-Quad, version 1; Illumina Inc.) with approxi-
mately 610,000 markers (including approximately 20,000
non-polymorphic markers) at the Center for Applied
Genomics (Children’s Hospital of Philadelphia, Philadel-
phia, PA USA). Total genomic DNA extracted from whole
blood was used in the experiments. Standard data-normal-
ization procedures and canonical genotype-clustering files
provided by Illumina were used to process the genotyping
signals. Concordance between SNPs from the arrays and
SNPs from exome sequencing was determined by calculat-
ing the percentage of variants from exome sequencing and
comparing this with the same genotype derived from the
SNP arrays.
Alignment and variant calling
BWA-GATK variant calling
Burrows-Wheeler aligner (BWA; version 0.5.9 [17]) was
used to align the sequencing reads, with default para-
meters, to the human reference genome sequence
GRCh37. Alignments were converted from sequence
alignment map (SAM) format to sorted, indexed binary
alignment map (BAM) files (SAMtools version 0.1.18;
http://sourceforge.net). The Picard tool was used to
remove duplicate reads. GATK software tools (version 1.5;
http://www.broadinstitute.org) were used for improvement
of alignments and genotype calling and refining with
recommended parameters [18]. BAM files were re-aligned
with the GATK IndelRealigner, and base quality scores
were re-calibrated by the GATK base quality recalibration
tool. Genotypes were called by the GATK UnifiedGenoty-
per, and the GATK VariantRecalibrator tool was used to
score variant calls by a machine-learning algorithm and to
identify a set of high-quality SNPs using the Variant Qual-
ity Score Recalibration (VQSR) procedure. GATK was
used to filter high-quality insertions and deletions (indels)
by hard criteria, ‘QD < 2.0, ReadPosRankSum < -20.0 FS >
200.0’. Finally, we removed SNVs and indels located out-
side of regions targeted by exome capture. To increase
sensitivity, only those indels with depth (DP) of 10 or
more, and with more than 4 reads supporting the indel
events were included in the final high-confidence indel set.
At a later date, one exome was processed with newer ver-
sions of the GATK v2.3-9 UnifiedGenotyper and GATK
v2.3-9 HaplotypeCaller modules.
BWA-SAMtools genotype calling
Using the above BAM files, we used SAMtools (version
0.1.18) to generate genotype calls [19]. The ‘mpileup’
command in SAMtools was used to identify SNPs and
indels, and we removed variants with DP coverage less
than 10, and variants located outside of exome-capture
regions.
SOAP pipeline
Adaptor and low-quality sequences were removed before
mapping. Sequence reads identified from each individual
were then aligned to human reference genome GRCh37
using SOAPaligner (version 2.21 [20]) with a maximum of
five mismatches. Duplicate reads were removed. Consen-
sus genotypes in target regions were called by SOAPsnp
(version 1.03) [21] with recommended parameters. SNV
results were filtered (Phred-like SNV quality ≥ 20, overall
depth 8 to 500, copy number estimate < 2, and distance
between two adjacent SNVs ≥ 5). For a heterozygous SNV,
the quality of the minor allele was required to be at least
20, depth of coverage for the minor allele at least 4, and
the ratio of major allele to minor allele less than 5. For
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assembly based on an extended de Bruijn graph [22]. For
SOAPindel, the aligner BWA was used to align the reads
to the human reference sequence with default parameters.
Initially, putative indels were assumed to be located near
the unmapped reads whose mates mapped to the refer-
ence genome. SOAPindel then executed a local assembly
(k-mer = 25) on the clusters of unmapped reads. Clusters
with coverage of less than 5 were not used. The assembly
results were aligned to the reference in order to find the
potential indels. To distinguish true-positive and false-
positive indels, SOAPindel generates Phred quality scores,
which take into consideration the depth of coverage, indel
size, number of neighboring variants, distance to the edge
of the contig, and position of the second different base
pair. Only those indels with a quality score of 10 or higher
were retained in the final indel call set.
GNUMAP pipeline
Diploid and monoploid SNVs for each individual were
called using the GNUMAP pipeline (version 3.1.0 [23]).
GNUMAP-SNP utilizes a novel probabilistic pair-hidden
Markov model, which accounts for uncertainty in the
read calls as well as read mapping in an unbiased fash-
ion. Raw reads were initially aligned to the full genome
using an alignment score of 260 or greater, which for
this dataset allowed for only one SNV per read. A
k - m e rs i z eo f1 2a n daj u m ps i z eo f1 0w e r ea l s ou s e d .
Only SNVs within exome regions with a P <0 . 0 0 1w e r e
reported. The GNUMAP pipeline cannot currently call
indels.
BWA-SNVer pipeline
BWA [17] was used to align the sequencing reads to
GRCh37 with default parameters. Duplicate reads were
removed by Picard, and SNVer (version 0.2.1) was then
used for detecting SNVs in each sample [24]. Similar to
GATK [18], only the mapped short reads with mapping
quality of greater than 20 were considered, and only
bases with base quality greater than 17 counted. SNVer
estimated the empirical error rate for those selected
reads in making variant calls. We set the number of
haploids to 2 for analysis of individual samples, and set
the variant allele frequency threshold of greater than 0
for detecting both rare and common SNVs. SNVer pro-
vides multiplicity control, and we performed Bonferroni
correction and controlled the family-wise error rate at
the 0.05 level to report identified SNVs. Indels cannot
currently be called by the BWA-SNVer pipeline.
Post-variant calling analyses
Post-variant-calling analyses were performed using
Golden Helix SVS (version 7.6.10 [25], ANNOVAR [26],
the R suite of statistical programming tools http://www.
r-project.org, and custom Perl scripts.
MiSeq sequencing for validation
Validation variants were randomly selected from sets of
particularly controversial variants, indels and SNVs unique
to GATK, indels and SNVs unique to SOAP, and variants
(both SNVs and indels) shared by these two pipelines.
PCR primers were designed using the software program
Primer 3 http://sourceforge.net, to produce amplicons
(ranging in size from 100 to 200 bp) containing variants of
interest in approximately the center of the amplicon. Pri-
mers were obtained in 96-well plate format, 10 μmol/L
dilution each (Sigma-Aldrich, St Louis, MO, USA). All pri-
mers were first tested for PCR efficiency using a HAPMAP
DNA sample (Catalog ID NA12864l Coriell Institute for
Medical Research, Camden, NJ, USA) and DNA polymer-
ase (LongAmp
® Taq DNA Polymerase; New England Bio-
labs, Beverly, MA, USA). k8101-49685 genomic DNA was
used as template for the validation experiment. After qual-
ity-control steps using agarose gel, the product was puri-
fied (ExoSAP-IT
® reagentsl Affymetrix Inc., Santa Clara,
CA, USA) and pooled. Final PCR products were quantified
(Qubit
® dsDNA BR Assay Kitl Invitrogen Corp., Carlsbad,
CA, USA), then library construction for the sequencer
platform (MiSeq Personal Sequencer; Illumina Inc.) was
performed. Finally, before being loaded onto the MiSeq
machine, the quality and quantity of the sample was veri-
fied using the Bioanalyzer (Agilent Technologies) and
quantitative PCR (Kapa Biosystems Inc., Woburn, MA,
USA).
Accessing data
All of the data have been submitted to the Sequence Read
Archive under project accession SRP019719, correspond-
ing to the 15 exomes and the single whole genome ana-
lyzed during the course of our study (see Additional file 2).
Results
Data production summary
Fifteen DNA samples from four different families (see
Additional file 1, Figure S1) were prepared by exon cap-
ture (Agilent 44 MB SureSelect protocol; Agilent Tech-
nologies), followed by sequencing on (HiSeq2000;
Illumina Inc.). On average, we obtained sequence cover-
age of approximately 120X (range, 100 to 154X) on tar-
geted regions for these 15 samples. For all samples,
sequence reads covered more than 80% of the targeted
region with a depth of greater than 20 reads per base
(see Additional file 1, Figure S2; for data production sta-
tistics, see Additional file 3). Five different pipelines
were used for read alignment and variant calling (SNVs
and indels when possible) (Table 1). In addition, one whole
genome was sequenced and analyzed by CG with 95% of
the exome region covered by 20 reads or more per base,
resulting in greater than 88% of the genome covered with a
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generated by CG with their in-house analysis pipeline
(version 2.0).
SNV analysis
Concordance with SNP genotyping arrays
Sensitivity and specificity for detecting common SNPs
was calculated for each Illumina variant-calling pipeline
for four samples that were genotyped with the Illumina
Human610-Quad version 1 SNP array (see Additional
file 1, Table S1). We caution that this analysis was
restricted to a set of common SNPs targeted by the SNP
array, and that these tend to be within regions contain-
ing little to no repeated sequences and without extreme
GC contents. Therefore, although widely used in pub-
lished literature, concordance with SNP arrays does not
adequately measure real-world performance on all var-
iants in personal genomes. With this major caveat in
mind, performance for each pipeline was measured by
treating the Illumina Human610-Quad version 1 SNP
arrays as a true-positive reference, and comparing the
exome-capture sequencing results with this reference
set. The average specificity for each of the five Illumina
pipelines was generally high, ranging from 99.59% to
99.87% (Table 2), consistent with the fact that each of
these pipelines have been optimized to minimize false
negatives for known common SNPs. The average sensi-
tivity ranged among the five pipelines from 86.6% (with
GNUMAP) to 95.3% (with GATK1.5). Sensitivity
decreased when the variant set was iteratively restricted
to the intersection between two or more variant-calling
pipelines, whereas specificity naturally shows the oppo-
site trend of increasing values under the same series of
intersections (Table 2).
Evaluation of performance by inheritance analysis
To explore the validity of SNVs called by each Illumina
pipeline, we performed an inheritance analysis for two
families contained within the 15 sequenced exomes. Pre-
vious calculations have estimated the average expected
number of de novo non-synonymous coding mutations
per individual exome to be approximately 1 to 2
[27-30]. However, we found that the number of putative
de novo mutations per child per exome was much
higher if only the parents of the child were used to filter
out inherited mutations. Adding an additional familial
generation to the filtering process, in our case a grand-
parent, significantly reduced the number of putative de
novo variants to a value comparable with that of the
previously reported value of expected de novo non-
synonymous mutations. In addition, significant variation
was seen in the number of putative de novo mutations
between the two families (Table 3), consistent with pre-
vious findings [31].
Table 1 A descriptive summary of the variant calling pipelines included in the comparative analyses.
Pipeline name Alignment method Variant-calling
module
Description of variant-calling algorithm
SOAP SOAPaligner version
2.21/BWA
version 0.5.9
SOAPsnp version
1.03/SOAPindel
version 2.01
SOAP uses a method based on Bayes’ theorem to call consensus
genotype by carefully considering the data quality, alignment, and
recurring experimental errors [22].
GATK version 1.5 BWA version 0.5.9 UnifiedGenotyper
version 1.5
GATK employs a general Bayesian framework to distinguish and call
variants. Error correction models are guided by expected characteristics of
human variation to further refine variant calls [19].
SNVer version 0.2.1 BWA version 0.5.9 SNVerIndiversion idual
version 0.2.1
SNVer uses a more general frequentist framework, and formulates variant
calling as a hypothesis-testing problem [25].
GNUMAP version 3.1.0 GNUMAP
version 3.1.0
GNUMAP version 3.1.0 GNUMAP incorporates the base uncertainty of the reads into mapping
analysis using a probabilistic Needleman-Wunsch algorithm [24].
SAMtools version 0.1.18 BWA version 0.5.9 mpileup version 0.1.18 SAMtools [20] calls variants by generating a consensus sequence using
the MAQ model framework, which uses a general Bayesian framework for
picking the base that maximizes the posterior probability with the highest
Phred quality score.
Table 2 Quality evaluation of variant detection using
different variant-calling pipelines.
Sensitivity Specificity
Mean* SD Mean* SD
SOAPsnp 94.68 2.26 99.79 0.03
GATK1.5 95.34 1.16 99.72 0.08
SNVer 92.33 4.40 99.78 0.04
GNUMAP 86.60 3.23 99.64 0.06
SAMtools 94.47 4.22 99.59 0.16
Any pipeline 97.67 1.20 99.62 0.11
≥ 2 pipelines* 96.64 2.28 99.69 0.07
≥ 3 pipelines* 95.62 3.13 99.73 0.05
≥ 4 pipelines* 92.60 3.40 99.82 0.04
5 pipelines* 80.58 5.26 99.87 0.01
*Intersection of variants contained in the number of pipelines specified.
Sensitivity and specificity was calculated for each pipeline by comparing
Illumina Human610-Quad version 1 SNP arrays with exome-capture
sequencing results, based on the four samples whose genotyping data was
available.
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SNV concordance between all 5 Illumina pipelines
across all 15 exomes was 57.4% on average, and Ti/Tv
ratios showed a generally increasing trend for sets of
variants intersected by an increasing number of variant-
calling pipelines (Figure 1). We found that for novel
SNVs (those not found in dbSNP135) the overall con-
cordance (11.4%) was much lower than the overall con-
cordance between known SNVs (59.6%) (Figure 1). In a
previous paper, we validated with Sanger sequencing or
Sequenom genotyping 17 SNVs found in 3 of the cur-
rent pilot samples [32]. Of these 17 validated SNVs, 16
were detected by all 5 pipelines, and the remaining var-
iant was called by 4 of the 5 pipelines. Additional valida-
tion analyses are presented later in this paper.
A more detailed analysis of SNVs of one sample
(k8101-49685) revealed that the exome variant calls had
moderate to high depth of coverage (see Additional file 1,
Figure S3). The range of read depths along with read-
depth uniformity of variant calls varied between pipelines
(see Additional file 1, Figure S3). Overall concordance
between all five pipelines for sample k8101-49685 was
57.5%; however, sub-setting variants called by Illumina
pipelines using increasingly stringent read-depth thresh-
olds did not increase SNV concordance (see Additional
file 1, Figure S4), and overall concordance was lowest
when read-depth threshold values were at their highest
(32.7% concordance when depth was required to be
greater than 30 supporting reads).
Sequencing platform concordance
For sample k8101-49685, we selected variants generated
by the CG pipeline that fell within the exon-capture
regions of the Agilent SureSelect version 2 capture kit.
We found that of the 21,050 SNVs identified by CG and
located within the UCSC refGene regions, 19,407 (92%)
were also within regions targeted for capture by the Agi-
lent SureSelect version 2 kit. Of these, 2,085 (11%) were
not called by any of the Illumina-based exome-analysis
pipelines, despite computed high mappability scores for
these variants (Figure 2) [33]. Of these 2,085 SNVs
uniquely called by CG, an average of 558 had no
sequence coverage as mapped by any of the Illumina-
based exome-analysis pipelines. The Illumina exome
read-depth for the remaining 1,527 CG-unique SNVs
was calculated, and the majority of these SNVs were
found to be in regions of very low Illumina sequence cov-
erage (< 20 reads) in the exome datasets (see Additional
file 1, Figure S5).
We found that 89.3% of CG SNVs (17,322 of 19,407)
were contained within the union of all five Illumina pipe-
lines (35,653 putative SNVs), whereas 18,331 of these
35,653 putative Illumina SNVs were not called by CG,
suggesting a high false positive rate in the union of the
Illumina calls and/or conversely a high false-negative rate
in the CG calls (Figure 2). Overall concordance displayed
marginal increases when VQLOW SNVs (low-quality
CG variants) were removed from the pool of CG SNVs
(Figure 2). Overall concordance remained stable as the
depth of coverage threshold value associated with Illumina
data calls increased (see Additional file 1, Figure S6A).
When only highly concordant Illumina SNVs (SNVs
called by all five Illumina pipelines) were compared with
the CG SNVs, only 64.4% (12507) of CG SNVs were
contained within the concordant Illumina set, suggesting
a high false-negative rate in this highly concordant Illu-
mina set. Overall agreement decreased as the depth of
coverage threshold value for Illumina calls increased,
consistent with an increasing false-negative rate (see
Additional file 1, Figure S6B).
Cross-platform comparison of unique-to-pipeline SNVs
SNVs from sample k8101-49685 that were uniquely
detected by only one of the five Illumina variant-calling
pipelines were compared with SNVs called by CG (see
Additional file 1, Figure S7). Of the SNVs uniquely called
by GATK, 809 of 1671 (48%) were concordant with CG
data. The concordance was much lower for the other
Table 3 De novo single-nucleotide variants (SNVs) were detected in two families contained within the 15 study
exomes.
Number of putative de novo coding non-synonymous or nonsense SNVs detected
Family 1 Without using the grandparents as a filter Using the grandparents as a filter
Child A 241 1
Child B 211 0
Child C 102 6
Child D 242 3
Family 2
Child A 49 NA
a
Child B 41 NA
a
aN/A, no grandparent available.
Family 1 had a grandparent available for filtering purposes, whereas family 2 did not. To minimize false positives in the pool of SNVs associated with each child,
only highly concordant SNVs were used (SNVs detected by all five pipelines). To construct a comprehensive set of SNVs for each parent, and hence increase
filtering accuracy, false negatives for parent SNVs were reduced by taking the union of all SNV calls from all five pipelines.
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The alignment method used, followed by the SNV variant calling algorithm is annotated here in shorthand: BWA-GATK, SOAP-Align-SOAPsnp,
BWA-SNVer, BWA-SAMtools, and GNUMAP-GNUMAP. (A) Mean SNV concordance between each pipeline was determined by matching the
genomic coordinate as well as the base-pair change and zygosity for each detected SNV. (B) The same analysis as in (A) but filtered to include
only SNVs already found in dbSNP135. (C) The same analysis as in (A), but filtered to include novel SNVs (that is, SNVs not found in dbSNP135).
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of 886 (5%) for SAMtools, 29 of 226 (12%) for SNVer,
and 24 of 908 (3%) for SOAPsnp. Concordance improved
for SNVs that were called by more than a single Illumina
data pipeline, and the concordance was the highest for
variants found by all five Illumina pipelines (see Addi-
tional file 1, Figure S7).
For variants that were novel as well as unique to a sin-
gle Illumina pipeline, concordance with CG data was
low (see Additional file 1, Figure S7). For GATK, 25%
(13 of 51) of novel and unique-to-pipeline SNVs were
concordant with CG data; for GNUMAP and SOAPsnp,
no novel and unique-to-pipeline SNVs were concordant
(0 of 470 and 0 of 229 respectively); for SAMtools, 0.2%
(1 of 418) of novel and unique-to-pipeline SNVs were
concordant; and for SNVer, 6% (1 of 18) of novel and
unique-to-pipeline SNVs were concordant. Concordance
rates of novel and unique-to-pipeline SNVs increased
for variants called by an increasing number of pipelines
(see Additional file 1, Figure S7).
Indel analysis
Variant-calling pipeline concordance
For indel calls, initial agreement between SOAPindel,
SAMtools and GATK was very low at 3.0% (see Additional
file 1, Figure S8). Indel coordinates were subsequently left-
normalized and intervalized using a total range of 20 geno-
mic coordinates (10 bp in each direction of their genomic
coordinates). We found that increasing the intervalized
indel range to as much as 60 genomic coordinates only
Figure 2 Single-nucleotide variant (SNV) concordance, between two sequencing pipelines (Illumina and Complete Genomics (CG)) for
a single exome, k8101-49685. For the Illumina sequencing, exons were captured using the Agilent SureSelect version 2 panel of capture
probes. CG SNVs consisted of a subset of all SNVs called by CG that fell within the Agilent SureSelect version 2 exons. Concordance was
determined by matching the genomic coordinates, base-pair composition, and zygosity status for each detected SNVs. Illumina SNVs consisted
of all SNVs (the union) called by the five variant-calling pipelines GATK, SAMtools, SOAPsnp, SNVer, and GNUMAP, which increased the false
positives but decreased the false negatives. Concordance was measured between Illumina SNVs and (A) all CG SNVs, (C) only high-quality
(VQHIGH) CG SNVs, and (D) only low quality (VQLOW) CG SNVs. (B) Genome mappability analyses were performed on 2,085 discordant SNVs,
which were found by the CG pipeline and not found by any of the five Illumina data pipelines.
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as a reasonable and conservative range for intervalizing
indels. This method increased the overall concordance to
26.8% between the three indel-calling pipelines (Figure 3).
For novel indels, the concordance (4.7%) was much lower
than the overall concordance among known indels
(43.3%). In an earlier paper, we previously validated with
Sanger sequencing three indels found in three of the cur-
rent pilot samples [32]. These three validated indels were
detected by all three indel-calling pipelines.
Sequencing platform concordance
Indels falling within the range of the Agilent SureSelect
version 2 exons were excised from the whole genome of
sample k8101-49685 sequenced and analyzed by CG.
Indels were again left-normalized and intervalized using
a total range of 20 genomic coordinates, 10 in either
direction. The normalized and intervalized CG indel
calls were compared with all normalized and interva-
lized indels detected by the three Illumina data pipe-
lines, and 32% were in agreement (Figure 4).
Cross-platform comparison of unique-to-pipeline
indels For the three Illumina data indel-calling pipe-
lines, unique-to-pipeline indels were compared with
indels discovered by CG (see Additional file 1, Figure
S9). Concordance with CG indels was relatively low for
all three pipelines with unique-to-GATK indels, showing
a concordance of 24% with CG indels (324 of 1366),
unique-to-SAMtools showing 29% concordance with CG
indels (142 of 498) and unique-to-SOAPindel having
12% of called indels being concordant with CG indels
(147 of 1246). Concordance rates improved for variants
that were called by two Illumina data pipelines and
further improved for variants called by all three of the
indel-calling pipelines, 63% (1241 of 1986) and 90% (963
of 1069), respectively.
Novel (to dbSNP135) and unique-to-pipeline indels
were also compared to CG indel calls, and the concor-
dance rates for each pipeline were similar to those of the
unique-to-pipeline only variants (see Additional file 1,
Figure S9). Novel and unique-to-GATK indels had 24%
of its indels concordant with CG indels (299 of 1236),
novel and unique-to-SAMtools had 28% of its indels con-
cordant with CG indels (96 of 343) and novel and
unique-to-SOAPindel had 5% of its indels concordant
with CG indels (53 of 1056). Novel indels that were called
by two Illumina data pipelines displayed an increased
concordance rate, 54% (229 of 423). Variants called by all
three of the indel-calling pipelines showed the highest
concordance rate for novel, unique-to-pipeline indels,
84% (103 of 122).
MiSeq validation of pooled PCR amplicons
To validate variants called by the two more widely used
p i p e l i n e s( S O A Pa n dG A T K ) ,w eu s e dt h eo r t h o g o n a l
approach of PCR amplification of genomic DNA regions
containing selected SNVs and indels, followed by pooled
MiSeq sequencing. The PCR amplification (instead of
exon capture), longer read lengths on the MiSeq plat-
form, and the much higher depth of coverage provided
a strong method of validation for SNVs and indels. A
total of 1,140 SNVs found in sample k8101-49685 were
selected for MiSeq validation; 760 of these SNVs were
randomly selected from the set of SNVs that were
unique to the GATK version 1.5 and SOAPsnp version
1.03 pipelines, 380 SNVs from each pipeline respec-
tively. An additional 380 SNVs were randomly selected
from the set of variants that were in agreement between
GATK and SOAPsnp. After some analysis of the quality
of the MiSeq data using FASTX, the MiSeq paired-end
read data (version 2 sequencing kit, 250 × 250 bp reads)
was trimmed to 150 bp and then aligned with BWA ver-
sion 0.6.2 to the human reference genome sequence
GRCh37, and variants were called with GATK Unified-
Genotyper version 2.3-9.
Of the 1,140 SNVs targeted for MiSeq validation, 919
(81.0%) were successfully amplified and sequenced, with
an average read depth of 5,392. Validation rates for
unique-to-GATK SNVs were high, with 306 of 315
(97.1%,) being successfully validated. For unique-to-
SOAPsnp, 174 of 289 SNVs (60.2%) were validated.
SNVs that were called by both GATK and SOAP were
validated in 312 of 315 instances (99.1%) (Figure 5).
For indels found in sample k8101-49685, 960 were ran-
domly selected for validation. Of these, 386 were ran-
domly selected from the unique-to-GATK indel set, 387
were randomly selected from the unique-to-SOAPindel
set, and 187 were randomly selected from set of indels
overlapping between the two (SOAPindel and GATK).
Of the 960 indels that were targeted for sequencing, 841
(83.5%) were successfully amplified and sequenced, with
an average coverage of 4,866.
Unique-to-GATK indels had a validation rate of 180
of 336 (54.0%), being validated. The validation rate for
unique-to-SOAPindel was found to be 44.6%, with 148
of 332 validating. For indels that were called by both
SOAPindel and GATK, 132 of 169 (78.1%) were suc-
cessfully validated (Figure 5).
GATK v2.3-9 and the new HaplotyperCaller
Newer implementations of SNV and indel-calling pipelines
continually advance the field of variant discovery and ana-
lysis by increasing the accuracy by which variants can be
reliably called. Here, we show an example of the differ-
ences between previous versions of GATK with respects
to SNV calls and indel calls on the same sample, k8101-
49685. The vast majority of SNV calls made by both the
GATK UnifiedGenotyper version 2.3-9 and the GATK
HaplotypeCaller version 2.3-9 modules overlapped with
O’Rawe et al. Genome Medicine 2013, 5:28
http://genomemedicine.com/content/5/3/28
Page 9 of 18Figure 3 Mean indel concordance over 15 exomes between 3 indel-calling pipelines: GATK, SOAPindel, and SAMtools.M e a n
concordance was measured between (A) all indels, (B) known indels (indels found in dbSNP135), and (C) unknown indels (indels not found in
dbSNP135). Indels were left normalized and intervalized to a range of 20 genomic coordinates (10 coordinates on each side of the normalized
position) to allow for a reasonably standardized indel metric for comparison. To determine whether or not indels were matching, the genomic
coordinates as well as the base length and composition of each indel were considered.
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sion 1.5, showing an overall concordance of 91.0% (27,150
of 29,912) and 87.0% (26,751 of 30779) respectively. How-
ever, for indel calls, the picture was quite different, with
the GATK UnifiedGenotyper version 2.3-9 and GATK
HaplotypeCaller version 2.3-9 modules showing an overall
concordance with the GATK UnifiedGenotyper version
1.5 calls of 54.7% (1,688 of 3,085) and 54.6% (1,858 of
3,404) respectively (see Additional file 1, Figure S10).
Discussion
Significant advances have been made in detecting genomic
variation in ‘next-generation’ sequencing data, despite con-
siderable sources of uncertainty [13]. However, we have
found that there still exists significant discrepancy between
the overall variant sets called by five different variant-call-
ing pipelines applied to the same raw sequencing data
using near-default parameters, along with differences
noted between two next-generation sequencing (NGS)
platforms. There are, of course, relatively large regions of
overlap between all pipelines even when highly specialized
parameterizations are not used. This suggests that there
exists a ‘region’ of variants that can be called robustly by
many different pipelines regardless of meticulous parame-
terization. The field has naturally focused on this robust
set of calls, but we wish to highlight here the considerable
degree of discordance as well as the high false-negative
rates.
A discussion about variant quality and the case for
multiple methods for sequence analysis in personal
genomes
For the five variant-calling pipelines included in our study,
a large number of calls (both SNV and indel) are shared
among them in each exome, 21,146 on average for SNVs.
Although all five pipelines converge on a relatively large
number of SNVs, this still represents less than 60% of the
total SNV call set determined by all five pipelines, and
hence there still exists a considerable degree of variation
between pipelines used, with near-default parameterization
on the same raw sequencing data. This disagreement is
likely to be the result of many factors including alignment
Figure 4 Indel concordance for a single exome, k8101-49685, between two sequencing pipelines: Illumina and Complete Genomics
(CG). Illumina indels consist of a union of all indels called by each of the three indel-calling pipelines GATK, SOAPindel, and SAMtools. CG indels
consisted of a subset of indels called by CG that fell within the Agilent SureSelect version 2 exons. Both Illumina and CG indels were left
normalized and intervalized to a range of 20 genomic coordinates (10 coordinates on each side of the normalized position). To determine
whether or not indels were matching, the genomic coordinates as well as the base length and composition of each indel were considered.
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tion efficacy of alignment and variant-calling algorithms,
and the underlying models utilized by the variant-calling
algorithm(s).
SAMtools, SOAPsnp, and GATK use similar Bayesian
methods to compute the posterior probability of the true
genotype [19,34-37], but they differ in the prior probabil-
ities used. For example, SAMtools (MAQ) sets the prior
probability for a heterozygous SNV at 0.001 for novel var-
iants, and 0.2 for known SNVs. SOAPsnp uses a more
complex method of assigning prior probabilities by distin-
guishing the homozygous genotype for the reference allele
from the homozygous genotype for the alternative, and
distinguishing transition (A↔G, C↔T) mutations from
transversion (A/G↔C/T) mutations. GATK is similar to
SAMtools but utilizes more advanced pre-processing and
post-processing steps, such as local re-alignment around
possible indel loci, and quality recalibration of both base
quality and variant quality to improve overall variant-call
performance. By modeling allele frequency, SNVer uses a
frequentist framework for calling variants [24]. SNVer for-
mulates variant calling as a hypothesis-testing problem so
that a prior probability is not required, and SNVer could
act as a complementary method to Bayesian methods.
GNUMAP, which employs a probabilistic Needleman-
Wunsch algorithm, might also be considered an orthogo-
nal method, as even its computational framework for
sequence alignment is novel [23].
Each variant-calling pipeline detects variants that others
do not, and the accuracy of these discordant variants is
expected to be low, but not zero. Indeed, for our compari-
son of SNVs called by SOAP, GATK, or both, MiSeq vali-
dation of unique-to-GATK and unique-to-SOAP variants
demonstrated relatively high rates of validation, with 306
of 315 of the randomly selected SNVs from unique-to-
GATK and 174 of 289 SNVs from unique-to-SOAPsnp
being validated. Indels had lower, but still non-zero, vali-
dation rates, with 180 of 336 unique-to-GATK indels and
148 of 332 unique-to-SOAPindel indels being validated.
Given that ‘unique-to-pipeline’ variants exist even in
regions of relatively high sequence coverage, it is necessary
to develop other approaches for including or excluding
these variants from downstream analyses.
In the realm of biomedical research, every variant call is
ah y p o t h e s i st ob et e s t e di nl i g h to ft h eo v e r a l lr e s e a r c h
design. Missing even a single variant can mean the differ-
ence between discovering a disease-contributing mutation
or not [38]. For this reason, our data suggest that using a
single bioinformatics pipeline for discovering disease-
related variation is not always sufficient. A more compre-
hensive approach can be taken; all variants discovered by
multiple variant-calling pipelines, when coupled with
appropriate no-calling and quality filtering, could be
included in downstream analyses, so as to not miss poten-
tially disease-contributory variants. This is something that
we intuitively implemented in a prior project [39], but for
which these data now provide empirical support.
One can minimize false positives by increasing strin-
gency filters, but this automatically and correspondingly
increases the false-negative rate. The intersection between
Figure 5 MiSeq validation experiment on a subset of Illumina-data calls. A total of 1,140 SNVs from sample k8101-49685 were randomly
sampled for MiSeq validation, with 380 sampled from the set of unique-to-GATK SNVs, 380 sampled from the set of unique-to-SOAPsnp SNVs,
and 380 sampled from the set that were overlapping between these two pipelines. There were 919 (81.0%) of these variants that were
successfully amplified and sequenced. BWA version 0.6.2 and GATK version 2.3-9 were used to process the sequencing data for variant-calling.
Additionally, 960 indels from sample k8101-49685 were randomly selected for validation. Of these, 386 were randomly selected from the unique-
to-GATK indel set, 387 were randomly selected from the unique-to-SOAPindel set, and 187 were randomly selected from the set of indels
overlapping between the two (SOAPindel and GATK). There were 841 (83.5%)of these indels that were successfully amplified and sequenced.
BWA version 0.6.2 and GATK version 2.3-9 were used to determine the number of variants that were also successfully validated across these sets.
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positive rate, but we have also shown that each pipeline
uniquely identifies some true variants. Hence, clinicians
and policy-makers should be aware that propagating for-
ward the intersection of variant calls will result in a high
false-negative rate with exome sequencing and WGS, and
we discuss below the advantage brought to bear on this
issue by studying families. Therefore, processing single
sample datasets from one sequencing platform with multi-
ple variant-calling pipelines should not be the long-term
solution for generating variant calls with high sensitivity
and specificity, and we discuss alternative approaches
below.
The case for indel standardization
Although the focus of most variant-calling software has
been on detecting SNVs, it is the case that large-scale
structural copy number variants and small indels are
known to also be a biologically relevant and prevalent
form of genetic variation [40,41]. Indeed, initial indel
mapping efforts revealed upwards of 800,000 indels in a
diverse population that map to known human genes,
some of which can be associated with genetic disease
[42,43], while recent estimates from the 1000 Genomes
Project [44] suggest a 10:1 ratio of SNVs to indels in
individual human genomes. Reliably detecting indels is
therefore a crucial component of constructing a com-
prehensive set of clinically relevant genetic variants.
In contrast to SNVs, few indel-calling tools have been
developed, so current knowledge of the existing variation
due to indels, as well as the clinical implications of indels,
has lagged. In spite of the fact that indel detection is
becoming an important aspect of structural-variant analy-
sis [40], indel calling is relatively imprecise and inaccurate.
For example, the position of an indel with respect to its
reference is, in many cases, ambiguous. An indel can often
be represented at any of multiple locations. Krawitz et al.
[45] designed an indel coordinate comparison metric, the
equivalent indel region (eir), for comparing indel calls
between pipelines, and GATK provides a tool which
attempts to normalize indel position by left-justifying the
indel within its multiple possible coordinate representa-
tions. Indeed, commonly used databases such as dbSNP
have not yet entirely addressed the imprecision of indel-
calling pipelines [45] and report only a single position for
an indel, which could lead to disparate clinical diagnoses/
outcomes between similarly affected individuals. We sug-
gest that a more comprehensive approach should be
taken, with all potential positions for each indel expressed
and accounted for, so that downstream analysis can take
advantage of the known existing ambiguity.
Our data demonstrates large discrepancies between
indel-calling pipelines and suggests potentially high num-
bers of false positives and/or false negatives. Although
putative false positives can be tested via modest resequen-
cing efforts, false negatives and ‘no-calls’ require large-
scale, often impractical, resequencing projects to discover
them. Because of this limitation, few data exist on false-
negative rates across pipelines, and inferring these rates
from unique calls between pipelines is likely to be inade-
quate. Indel frequency, indel size, read length, and read
depth are all known to affect the accuracy of indel-calling
pipelines, and the performance of different pipelines also
depends, in part, on experimental conditions [46]. We
show that a relatively simple method can increase compar-
ison accuracy for indels between pipelines and between
individuals; left-normalized and intervalized indel calls
allow rapid and reasonable comparison of called indels
between different indel-calling pipelines, as well as
between individuals who have had their genome or exome
sequenced. The issues highlighted in our indel compari-
sons demonstrate the difficulties associated with attaining
accurate and standardized indel calls, and our data illus-
trate the need for robust and ubiquitous indel standardiza-
tion metrics/methods to allow for objective comparisons
across pipelines and across sequencing projects.
The case for studying large families for discovering
disease-related genetic variation
Our analysis of two families, one containing only two
generations (parents and children) and the other contain-
ing three generations (one grandparent, both parents,
and children) demonstrates that the ability to accurately
distinguish den o v ovariants from familial inherited var-
iants may be more strongly limited by high false-negative
rates in the parents than by high false-positive rates in
the children. This can be significantly improved by hav-
ing sequence data from one or more grandparents or
other relatives. This finding is particularly salient for sin-
gle-generation de novo studies, which attempt to charac-
terize novel variants that are associated with genetic
disease observed in the children of healthy parents
[47-51]. While such ‘no-call’ or false-negative errors in
parents can be ameliorated somewhat with higher
sequencing depth and/or more comprehensive variant-
calling strategies, larger and more comprehensive pedi-
grees provide a powerful, complementary source for dis-
covering and studying human genetic variation. Although
most studies utilizing NGS data to date have focused on
‘quads’ or ‘trios’ [47-51], studying large and/or consan-
guineous families can maximize the utility of filtering
strategies and statistical approaches for identifying dis-
ease-contributory variants in genetic disease [52].
The case for different platforms for a more
comprehensive “exome”
The relative merits of WGS are expanding as both the
cost of the technique decreases and as more scientists
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ber of studies/analyses [5,30,53,54]. We have shown that
WGS with the version 2.0 CG pipeline delivers SNVs
and indels not discovered by the Agilent exon capture
and Illumina sequencing, and that these variants have a
very low number of reads (< 20) at those positions in
the Agilent exomes, arguing that the capture of those
regions was not efficient. Conversely, there were a sig-
nificant number of variants in our data that were unani-
mously called by the five Illumina variant-calling
pipelines but not by the CG WGS. Exon capture and
sequencing at high depth with one platform can yield a
much higher depth of coverage in most exonic regions,
whereas WGS offers a more uniform and comprehen-
sive coverage that appears to cover regions missed by
exon capture and sequencing. To attain a truly compre-
hensive set of exonic variants, WGS on one platform
could be combined with exon capture and sequencing
on a different platform. This combination of the depth
of exonic sequencing provided by exon capture with the
breadth of coverage of WGS on a different sequencing
platform, alongside the use of multiple variant-calling
pipelines, provides a powerful means to maximize sensi-
tivity and specificity for any one personal genome. How-
ever, as costs for sequencing are reduced, we anticipate
that sequencing whole genomes on two or more plat-
forms may become a feasible option for similarly maxi-
mizing accuracy.
The current state of variant discovery
Many of the most recent advancements that have been
made in variant discovery and sequencing analysis are
those related to indel discovery and analysis. Indeed,
newer versions of GATK have improved upon the false-
negative and false-positive rates of their indel calls in both
UnifiedGenotyper and with the newer HaplotypeCaller. By
leveraging local de novo assembly, similarly to the SOA-
Pindel pipeline used in this study, the new HaplotypeCal-
ler from GATK potentially greatly improves upon its
indel-calling accuracy. The more distinct differences
observed between GATK indel calls by different versions
reflects the fact that indel discovery is in the earlier stages
of development, when large differences are often observed
between and within pipelines, with accuracy potentially
remaining relatively low. For example, in each pipeline,
SNV calling relies on set algorithms, which are not drama-
tically changed in updated versions of the software. There-
fore, we do not see great leaps in accuracy for SNVs with
newer versions of GATK, despite the fact that we found in
the current study that at least one other pipeline (SOAP)
did uniquely discover some validated SNVs that were not
discovered by any other pipeline or any version of BWA-
GATK tested here, and vice versa.W ea l s on o t et h a t
GATK discovered comparatively more unique SNVs not
discovered by any other pipeline. One caveat is that we
p r o c e s s e dt h eM i S e qd a t aw i t ht h en e w e s tB W A - G A T K
pipeline, so this might favor the exome variants previously
called by GATK, but it is nonetheless the case that SOAP
identified variants that GATK missed in the same exome
data using near-default parameters.
Some limitations of our study
I ti si m p o r t a n tt on o t et h a to u rs t u d yd i dn o te x a m i n e
somatic mutations in tumor samples, so our conclusions
and our testing pipelines focus only on germline muta-
tions from diploid genomes. We recognize that variant
calling in cancer genomes represents similar but some-
what distinct challenges, and that software tools (such as
SNVMix [55]) are typically developed specifically for
somatic mutations in cancer genomes. Our efforts were
designed to evaluate whether or not rare variants within
personal genomes can be reliably and comprehensively
generated from sequencing data, with or without sequen-
cing data from other family members. Hence, we did not
evaluate pipelines that specifically employ imputation or
multi-unrelated-sample variant-calling algorithms, such as
Thunder [56], IMPUTE2 [57-59], or BEAGLE [60,61], or
specific procedures within the software tools used that
allow for calling of multiple unrelated sample (such as
those available by GATK) [13].A d d i t i o n a l l y ,s o f t w a r e
tools that are only commercially available (such as
CLCBio) are not evaluated in our comparative study.
Conclusions
We have shown that there remains significant discrepancy
in SNV and indel calling between many of the currently
available variant-calling pipelines when applied to the
same set of Illumina sequence data under near-default
software parameterizations, thus demonstrating funda-
mental methodological variation between these commonly
used bioinformatics pipelines. In spite of this methodologi-
cal variation between pipelines, there exists a set of robust
calls that are shared between all pipelines even under lax
parameterization. We have further shown that the rela-
tively recent CG version 2.0 WGS pipeline detects a set of
exon variants that are not detected by several variant-
calling pipelines with an Illumina-based exon-capture
sequencing strategy, even in regions of high mappability
[33]. Therefore, each single existing exon-capture, NGS
platform, or variant-calling pipeline is likely to miss some
true functional rare variants. Some authors have suggested
using two separate sequencing platforms on the same
samples [10], while others have suggested that technical
replicates for exon capture may help to further improve
accuracy of heterozygote variant calls [62]. With current
technologies and cost considerations, exon capture and
deep sequencing combined with WGS is still too expen-
sive for most laboratories, and is therefore not likely to be
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best combination of depth and breadth of coverage for
genetic analyses of selected exonic regions. As an alterna-
tive, considering current prices, we suggest that utilizing
the total list of variants derived from multiple (and ortho-
gonal) variant-calling pipelines is a more feasible first
option for reducing false negatives in a discovery setting.
However, we fully acknowledge that in this scenario, the
rates of false positives and false negatives are inversely and
directly dependent on one another; that is decreasing the
false-positive rate with filters will increase the false-nega-
tive rate, and vice versa [63]. We have demonstrated that
studying larger multi-generational families can increase
the accuracy for de novo v a r i a n t s .W ea l s on o t et h a tt h e
standardization of indel discovery and reporting in a way
that allows more accurate comparison of indels between
sequencing platforms, variant-calling pipelines, and most
importantly between individuals in a population is a criti-
cal step that needs to be addressed before this functionally
important class of variants can be comprehensively
assessed in either a research or a clinical setting.
Description of additional data files
The following additional data are available with the
online version of this paper.
Additional file 1 is a Table and 10 supplementary
figures:
Figure S1, Family pedigrees contained within the
15 sequenced exomes. Of the fifteen exomes that were
sequenced, 14 were sequenced from families chosen for
future disease discovery related work. Each sequenced
individual (numbered) is displayed in the context of his
or her constituent family pedigree.
Figure S2, Fraction of target capture region covered
versus coverage depth for 15 exomes. All exomes have
at least 20 reads or more per base pair in > 80% or
more of the 44 MB target region.
Figure S3, Histograms of Illumina read depth at SNV
coordinates. Read depth taken from each pipeline’s inde-
pendently aligned BAM file at genomic coordinates of
SNVs called by each of the 5 alignment and variant calling
pipelines. A) SOAPsnp, B) SNVer, C) SAMtools, D)
GNUMAP and E) GATK, respectively. Frequency of read
depths for all SNVs (A, B, C, D,a n dE)a sw e l la sf o r
SNVs having depths between 0 and 50 (a, b, c, d,a n de)
were plotted.
Figure S4, SNV concordance measured at varying
Illumina read depth threshold values. SNV concordance
for a single exome, “k8101-49685”, between five alignment
and variant detection pipelines: GATK, SOAPsnp, SNVer,
SAMtools, and GNUMAP. Concordance between each
pipeline was determined by matching the genomic coordi-
nate as well as the base pair change and zygosity for each
detected SNV. Concordance was measured at varying
Illumina read depth threshold values in each indepen-
dently aligned BAM file, ranging from > 0 (no threshold)
to > 30 reads.
Figure S5, Histograms of illumina read depth at
genomic coordinates of the unique to Complete Geno-
mics SNV calls. Histograms of read depth taken from
each of the five Illumina pipeline’s independently aligned
BAM file at genomic coordinates of SNVs that were found
by Complete Genomics but not by any of the 5 Illumina
p i p e l i n e s :G A T K ,G N U M A P ,S N V e r ,S A M t o o l sa n d
SOAPsnp, A, B, C, D and E respectively. All coordinates
fell within the range of the Agilent SureSelect v.2 exons.
Figure S6, SNV concordance for a single exome,
“k8101-49685”, between two sequencing pipelines:
Illumina and Complete Genomics. For the Illumina
sequencing, exons were captured using the Agilent Sure-
Select v.2 panel of capture probes. Complete Genomics
SNVs consist of a subset of all SNVs called by CG that
fell within the Agilent SureSelect v.2 exons. Concor-
dance was determined by matching the genomic coordi-
nates, base pair composition, and zygosity status for
each detected SNV. Concordance was measured
between CG SNVs and A) the union of all SNVs called
by 5 variant calling pipelines ("Illumina-data calls”)a n d
B) only SNVs that all 5 Illumina pipelines collectively
called ("concordant Illumina-data calls”).
Figure S7, Cross-validation of illumina SNV calls
using Complete Genomics SNV calls. SNVs called by
each Illumina-data pipeline were cross-validated using
SNVs called by Complete Genomics, an orthogonal
sequencing technology, in sample “k8101-49685”.T h e
percentage of Illumina SNVs that were validated by CG
sequencing was measured for variants having varying
degrees of Illumina-data pipeline concordance. The
same analysis was performed for variants that were con-
sidered novel (absent in dbSNP135).
Figure S8, Average indel concordance among 15
exomes between three indel detecting pipelines:
GATK, SAMtools and SOAPindel. Concordance was
measured between raw, pre-standardized, indel calls.
Indels were considered in agreement if the genomic
coordinates, length and composition of indels matched
between pipelines
Figure S9, Cross-validation of illumina indel calls
using Complete Genomics indel calls. Indels called by
each Illumina-data pipeline were cross-validated using
indels called by Complete Genomics for sample “k8101-
49685”. The percentage of Illumina indels that were
validated by CG sequencing was measured across vary-
ing degrees of Illumina pipeline concordance. The same
analysis was done for novel indels (indels not found in
dbSNP 135).
Figure S10, A comparison between recent versions of
various GATK variant calling modules.T h es i m i l a r i t y
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Page 15 of 18between SNV and indel calls made between two versions
of GATK, v1.5 and v2.3-9, was measured. SNV and indel
calls were made using both the UnifiedGenotyper and Hap-
lotypeCaller modules on the same k8101-49685 participant
sample. Pairwise comparisons were made between the
GATK UnifiedGenotyper v1.5 and each of the GATK v2.3-
9 modules (the UnifiedGenotyper and HaplotypeCaller).
T a b l eS 1 ,C o n c o r d a n c er a t e sw i t hc o m m o nS N P s
genotyped on Illumina 610K genotyping chips.
Additional file 2 contains command-line arguments
for bio-informatics pipelines and instructions for acces-
sing data analyzed in this paper.
Additional file 3 contain data production statistics.
Additional material
Additional file 1: Figure S1-S7.
Additional file 2: Command-line arguments for bio-informatics
pipelines and instructions for accessing data analyzed in this paper.
Additional file 3: Data production statistics.
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